Akston Biosciences Corporation: Company Profile

Background

Overview

Akston Biosciences Corporation, founded in 2011, is a biotechnology company headquartered in Beverly, Massachusetts. The company is dedicated to developing and manufacturing protein-based therapeutics specifically designed for companion animals, aiming to provide innovative and affordable biotech solutions for pets.

Mission and Vision

Akston's mission is to deliver cost-effective, long-acting biologic therapies for chronic animal diseases, bridging the gap between human and pet healthcare. The company's vision is to revolutionize pet health by developing therapies that enhance the quality of life for pets and their families.

Primary Area of Focus

The company specializes in creating novel protein therapies tailored for companion animals, utilizing its proprietary Ambifect® Fc-fusion protein platform. This platform supports species-specific development for targeted care, ensuring that treatments are both effective and accessible.

Industry Significance

Akston operates within the rapidly growing pet care market, which was valued at over $152 billion in 2024, with $39.8 billion allocated to veterinary care and medications. The pet medicine sector is expanding at an annual rate of 6.6%, driven by the increasing prevalence of chronic conditions in aging pets.

Key Strategic Focus

Core Objectives

• Innovation in Pet Health: Developing advanced biologic therapies that address unmet needs in companion animal healthcare.

• Affordability and Accessibility: Ensuring that cutting-edge treatments are accessible to a broad range of pet owners.

• Long-Acting Therapies: Creating therapies that reduce the frequency of administration, enhancing convenience for both pets and their owners.

Specific Areas of Specialization

• Chronic Disease Management: Focusing on conditions such as diabetes, cancer, and obesity in pets.

• Immuno-Oncology: Developing immunotherapies that harness the pet's immune system to fight cancer.

• Metabolic Disorders: Addressing weight management and related metabolic issues in companion animals.

Key Technologies Utilized

• Ambifect® Fc-Fusion Protein Platform: A proprietary technology that enables the development of long-acting biologic therapies tailored for pets.

• GMP-Compliant Manufacturing: Operating a Good Manufacturing Practice (GMP) facility to ensure high-quality production standards.

Primary Markets Targeted

• Veterinary Clinics and Hospitals: Providing advanced treatment options for chronic conditions in companion animals.

• Pet Owners: Offering accessible and effective therapies to improve the health and well-being of pets.

Financials and Funding

Funding History

Akston has raised over $18 million in equity financing from private investors and the management team. Additionally, the company has secured $10 million from National Institutes of Health (NIH) grants and The Helmsley Charitable Trust.

Recent Funding Rounds

• May 14, 2022: Completed a funding round raising $5.2 million.

Notable Investors

The funding sources include private investors, the management team, NIH grants, and The Helmsley Charitable Trust.

Utilization of Capital

The capital raised is intended to support the advancement of Akston's product pipeline, expansion of manufacturing capabilities, and the commercialization of its therapies for companion animals.

Pipeline Development

Key Pipeline Candidates

• AKS-701d: An anti-cPD-L1 monoclonal antibody immunotherapy for canine bladder cancer, currently in pilot studies.

• AKS-705a: A biologic therapy for canine dermatitis.

• AKS-709p: A treatment targeting pain relief in osteoarthritis.

• AKS-711o: An antibody therapy for pet obesity.

Stages of Clinical Trials or Product Development

• AKS-701d: Undergoing pilot studies for canine bladder cancer.

• AKS-705a: In preclinical development for canine dermatitis.

• AKS-709p: In preclinical development for osteoarthritis pain relief.

• AKS-711o: In preclinical development for pet obesity.

Target Conditions

• AKS-701d: Canine bladder cancer.

• AKS-705a: Canine dermatitis.

• AKS-709p: Osteoarthritis pain in dogs.

• AKS-711o: Obesity in companion animals.

Anticipated Milestones

Specific timelines for clinical trial results and product launches are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

• Ambifect® Fc-Fusion Protein Platform: Enables the development of long-acting biologic therapies tailored for pets, reducing the need for frequent dosing.

Significant Scientific Methods

• Fc-Fusion Technology: Utilized to enhance the stability and duration of therapeutic proteins, improving treatment efficacy and convenience.

• GMP Manufacturing Practices: Ensures high-quality production standards for biologic therapeutics.

Leadership Team

Key Executives

• Todd Zion, Ph.D.: President and CEO. Dr. Zion co-founded Akston and has a background in biotechnology, having previously developed the world's first clinical glucose-responsive insulin at SmartCells, Inc.

• Thomas Lancaster, Ph.D.: Chief Scientific Officer. Dr. Lancaster leads Akston's scientific initiatives, focusing on the development of novel biologic therapies for companion animals.

• Thillainaygam Sathiyaseelan, Ph.D.: Vice President, Quality and Regulatory Affairs. Dr. Sathiyaseelan oversees quality control and regulatory compliance for Akston's products.

• Sylaja Murikipudi, Ph.D.: Senior Director of Quality Control. Dr. Murikipudi is responsible for ensuring the quality and safety of Akston's therapeutics.

• Manuel Valerio: Senior Director of Manufacturing Operations. Mr. Valerio manages Akston's manufacturing processes, ensuring efficient production of biologic therapies.

• Lauren Martin: Director of Human Resources. Ms. Martin oversees human resources functions, supporting Akston's growing team.

• Kristina Kalevas Camp, DVM, Ph.D.: Director of Regulatory Affairs – Biologics. Dr. Kalevas Camp manages regulatory affairs for Akston's biologic products.

• Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA: Director of Clinical Development – Biologics. Dr. Borgatti leads clinical development efforts for Akston's biologic therapies.

Competitor Profile

Market Insights and Dynamics

The global pet care market is experiencing significant growth, with increasing expenditures on veterinary care and medications. This growth is driven by the rising prevalence of chronic diseases in aging pets and a growing awareness among pet owners about the importance of advanced healthcare for their animals.

Competitor Analysis

• Zoetis Inc.: A leading global animal health company offering a broad range of medicines and vaccines for pets and livestock.

• Elanco Animal Health Incorporated: Provides a comprehensive portfolio of products to improve animal health and food safety.

• Vetoquinol S.A.: A global animal health company specializing in the research, development, and marketing of veterinary medicines and health products.

Strategic Collaborations and Partnerships

• Dechra Pharmaceuticals PLC: Akston partnered with Dechra to commercialize once-a-week canine and feline insulin therapies, leveraging Dechra's expertise in animal health.